Tuesday, July 23, 2019
wellness India Expo
Home Tags FDA

Tag: FDA

CDSCO issues alert on Medtronic’s pacemakers, company says no product recall

The CDSCO has advised patients with specific pacemakers from Medtronic to seek immediate medical assistance if they feel dizzy, light-headed, severe short breath or loss of consciousness. Meanwhile, the company has said it is in talks with the regulator............

Lupin Bioresearch Centre completes fifth successful US-FDA inspection

Lupin Bioresearch Centre (LBC) conducts the in-vivo and in-vitro bioequivalence studies for Lupin in Pune...................

“AI has the potential to revolutionize healthcare delivery”

Mentioned Dr Geetha Manjunath, CEO & CTO of Bangalore-based healthtech startup NIRAMAI in an exclusive interaction with BioVoice where she spoke about the artificial intelligence in healthcare and an innovative early breast cancer detection technology developed by her company...….

Global home diagnostics market revenues to surpass US$ 6.3 million by...

As per a Fact.MR study, increasing preference for self-diagnosis continues to be a trigger for home diagnostics sales, whereas a combination of industry-specific and regulatory factors continue to influence the strategies of market players...………..

Indian medical device firms be given faster access to US-FDA: study

Indian medical device industry is worth over Rs 60,000 crore even as country’s import bill for this segment amounts to over Rs 23,000 crore while exports amount to about Rs 7,000 crore, as per the study by ASSOCHAM and MRSS India...………..

Regulatory support, big pharma interest will boost precision medicine for cancer

The leading market analysis firm, GlobalData has predicted that the precision medicine approaches for for tumor agnostic development will accelerate due to the enhanced regulatory support and interest from big pharmaceutical players in the market...………..

US FDA approves Mylan & Biocon’s biosimilar, Fulphila

Second FDA-approved biosimilar through the Mylan-Biocon collaboration,, Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection...............

Pricing adjustments for CAR-T therapies likely to take place in 2018,...

A fairly comprehensive study reported in February 2018 on the Health Affairs Blog claims that Novartis could lower the price of Kymriah by two-thirds and still achieve a profit..................

Amneal & Impax merger to create 5th biggest pharma generics firm...

Combined company to benefit from expanded generics product portfolio, premier diversified generics pipeline, broad R&D capabilities across dosage forms, high-quality and low-cost global manufacturing and distribution network, and enhanced financial foundation........

Aplagon partners with Cadila to develop & test antithrombotic products in...

Aplagon has partnered with Cadila Pharmaceuticals to develop and commercialize APAC First-in-Class antithrombotics for the prevention of blood vessel occlusions related to vascular interventions..........